Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Oneal

Neurology Birmingham, AL Medical Doctor

NPI 1235134735 CMS profile 939329

2660 10Th Ave South, Suite 520, Birmingham, AL 35205

Open in the dashboard

General payments

$2,236

113 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Oneal of Birmingham, AL is reported in the CMS Open Payments database as having received $2,236 across 113 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 56th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,787 86
2024 General $125 6
2023 General $66 3
2022 General $12 1
2021 General $12 1
2020 General $63 4
2019 General $172 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Oneal
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to David Oneal were reported at $1,787. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year David Oneal Neurology median Middle half National median
2019 $172 $474 $118–$2,177 $163
2020 $63 $367 $82–$2,309 $114
2021 $12 $438 $104–$2,547 $132
2022 $12 $442 $103–$2,388 $149
2023 $66 $464 $119–$2,312 $160
2024 $125 $468 $119–$2,323 $164
2025 $1,787 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $271 15 payments
  2. UCB, Inc. $258 13 payments
  3. Otsuka America Pharmaceutical, Inc. $168 11 payments
  4. ACADIA Pharmaceuticals Inc $158 9 payments
  5. Biogen, Inc. $143 7 payments
  6. Sunovion Pharmaceuticals Inc. $127 9 payments
  7. Eisai Inc. $126 4 payments
  8. Pfizer Inc. $91 4 payments
  9. Neurocrine Biosciences, Inc. $91 4 payments
  10. Neurelis, Inc. $76 3 payments
  11. Other $727 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,190 110 payments
  2. Education $46 3 payments
Products named General payments · program years 2019–2025
  1. Leqembi $269 11 payments
  2. UBRELVY $227 13 payments
  3. Briviact $184 10 payments
  4. QULIPTA $168 9 payments
  5. REXULTI $168 11 payments
  6. NUPLAZID $158 9 payments
  7. APTIOM $127 9 payments
  8. NURTEC ODT $91 4 payments
  9. ZAVZPRET $91 4 payments
  10. INGREZZA $91 4 payments
  11. Other $838 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 82 drugs

Part D claims

5,568

Median for Neurology: 833

Drug cost

$2,444,145

Median for Neurology: $202,670

Branded share of claims

27.7%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Soliris Eculizumab Brand 13 $641,889
Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 Brand 53 $332,089
Octagam Immun Globg(Igg)/Malt/Iga Ov50 Brand 29 $288,178
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 33 $206,650
Aubagio Teriflunomide Brand 12 $110,351
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 31 $102,883
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 22 $95,221
Qulipta Atogepant Brand 85 $89,305
Ubrelvy Ubrogepant Brand 51 $70,915
Nurtec Odt Rimegepant Sulfate Brand 36 $64,041

The 10 drugs with the highest cost, of 82 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$75,924

Medicare's payments for the services billed

Medicare patients

284

Average age 74

Services billed

1,081

163 women, 121 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Ischemic heart disease 41%
Chronic kidney disease 33%
Diabetes 31%
Depression 30%
Atrial fibrillation 26%
Alzheimer's or dementia 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
  • PFIZER INC. $32
$32 36 —
ZAVZPRET
  • PFIZER INC. $32
$32 — —
UBRELVY
  • AbbVie, Inc. $30
$30 51 —
FYCOMPA
  • CATALYST PHARMACEUTICALS, INC. $17
$17 — —
QULIPTA
  • AbbVie, Inc. $7
$7 85 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

113 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record